Cocaine Use Disorder Market Size in the 7MM is expected to grow by 2034, according to DelveInsight

The Cocaine Use Disorder Market in the 7MM is projected to grow at a robust CAGR during the study period (2020–2034). DelveInsight’s Comprehensive market research provides critical insights into such market trends, enabling stakeholders to understand growth drivers, emerging opportunities, and potential challenges within the Cocaine Use Disorder Market Landscape. By analyzing historical data, current Cocaine Use Disorder Market Dynamics, and future projections, DelveInsight equips pharmaceutical companies, investors, and healthcare professionals with actionable intelligence to make informed strategic decisions, identify investment opportunities, optimize product positioning, and plan research and development initiatives effectively.

The Cocaine Use Disorder Market is increasingly guided by biomarker-driven strategies. Cocaine Use Disorder is a substance use disorder characterized by the compulsive and problematic use of cocaine despite harmful physical, psychological, social, or occupational consequences. It involves a loss of control over cocaine intake, intense cravings, and continued use even when it leads to health issues such as cardiovascular complications, neurological effects, mood disturbances, anxiety, and increased risk of overdose. Over time, repeated cocaine use alters brain reward pathways, reinforcing dependence and making cessation difficult without treatment, which may include behavioral therapies, counseling, and supportive interventions to manage cravings and prevent relapse.

DelveInsight’s report, “Cocaine Use Disorder Market Insights, Epidemiology, and Market Forecast-2034,” provides a comprehensive analysis of the Cocaine Use Disorder Market landscape. The report delivers detailed insights into the disease, including historical and projected epidemiology, helping stakeholders understand the prevalence, incidence, and patient demographics across key regions. Additionally, it examines Cocaine Use Disorder Market Dynamics, offering a thorough assessment of current and emerging market trends, treatment patterns, and therapeutic developments. The analysis spans major markets, including the United States, EU4 (Germany, Spain, Italy, France, and the United Kingdom), and Japan, equipping decision-makers with actionable intelligence for strategic planning, investment, and research initiatives.

To know in detail about the Cocaine Use Disorder Market Outlook, drug uptake, treatment scenario, and epidemiology trends, click here @ Cocaine Use Disorder Market Forecast

Key Takeaways from the Cocaine Use Disorder Market Report

• The leading Cocaine Use Disorder Companies, such as STALICLA, Embera NeuroTherapeutics, and others.

• Promising Cocaine Use Disorder Therapies such as EMB-001, NS2359, AFQ056, Buprenorphine + Naltrexone, Quetiapine, Risperidone, Brexpiprazole, and others.

• The Cocaine Use Disorder Market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching multiple-stage Cocaine Use Disorder Pipeline products will significantly revolutionize the Cocaine Use Disorder Market Dynamics.

Cocaine Use Disorder Overview

Cocaine Use Disorder is a chronic, relapsing brain condition in which repeated cocaine exposure disrupts normal dopamine signaling, driving intense reward-seeking behavior and impairing judgment, impulse control, and decision-making. Rather than occasional misuse, the disorder reflects a cycle of binge use, crash, and craving that progressively dominates daily life, often leading to sleep disturbances, paranoia, mood instability, cardiovascular strain, and social or occupational decline. Its persistence stems not only from psychological dependence but also from lasting neurobiological changes, making long-term recovery dependent on structured treatment, behavioral therapies, and sustained support rather than willpower alone.

Get a Free sample for the Cocaine Use Disorder Market Report @ https://www.delveinsight.com/report-store/cocaine-use-disorder-market

Key Trends in Cocaine Use Disorder Market

• Rising Disease Burden Driving Market Growth

The prevalence of cocaine use disorder continues to rise across major markets, particularly in the US and Europe, driven by increased cocaine availability, higher purity levels, and polysubstance use. This growing patient pool is expanding the overall treatment-seeking population and strengthening long-term market potential.

• High Unmet Need Due to Lack of Approved Therapies

There are currently no FDA-approved pharmacological treatments specifically indicated for cocaine use disorder. This absence of approved therapies highlights a significant unmet medical need and creates substantial opportunities for innovation and future market entry by effective disease-modifying treatments.

• Expanding and Diversifying Clinical Pipeline

The pipeline for cocaine use disorder is gradually expanding, with multiple investigational agents targeting neurotransmitter modulation, craving reduction, and relapse prevention. Increased clinical activity reflects growing interest from biopharmaceutical companies in addressing this historically underserved therapeutic area.

• Shift Toward Mechanism-Based and Combination Approaches

Emerging therapies are increasingly focused on mechanism-driven approaches, including glutamate modulation and dopamine regulation. In addition, combination strategies that integrate pharmacotherapy with behavioral interventions are gaining attention to improve long-term abstinence and treatment adherence.

• Behavioral Therapies Continue to Dominate Current Care

In the absence of approved drugs, behavioral interventions such as cognitive behavioral therapy and contingency management remain the cornerstone of treatment. These approaches continue to shape the current market landscape and are expected to remain essential even after pharmacotherapies enter the market.

• Increasing Focus on Early Diagnosis and Intervention

Improved screening tools, greater awareness of substance use disorders, and reduced stigma are leading to earlier diagnosis of cocaine use disorder. Early intervention is expected to improve treatment outcomes and gradually expand the addressable market size.

Cocaine Use Disorder Epidemiology Segmentation in the 7MM

The Cocaine Use Disorder Market Report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into-

• Total Cocaine Use Disorder Diagnosed prevalent cases
• Cocaine Use Disorder Gender-specific cases
• Cocaine Use Disorder Age-specific cases
• Cocaine Use Disorder Severity-specific cases
• Total Cocaine Use Disorder Treated cases

Download the report to understand which factors are driving Cocaine Use Disorder Epidemiology trends @ Cocaine Use Disorder Epidemiology Forecast

Recent Development in the Cocaine Use Disorder Treatment Landscape

• In May 2025, University of Massachusetts, Worcester conducted a study is a 4-site, 12-week, novel, feasibility, investigation of patients who have co-occurring diagnoses of schizophrenia and current substance use disorder (alcohol, cocaine, heroin, or cannabis). Thirty-nine participants will be randomly assigned to switch to brexpiprazole (the brexpiprazole group) or remain on the same antipsychotic treatment (the control group). The study will be conducted at 4 sites in the US. The investigators expect to enroll 80 subjects across 3 sites. UMass Medical School, Worcester MA is the lead site. Sub-sites include Massachusetts General Hospital (MGH) and the University of North Carolina at Chapel Hill (UNC).

Cocaine Use Disorder Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential Cocaine Use Disorder drugs recently launched in the Cocaine Use Disorder market or expected to get launched during the study period. The analysis covers Cocaine Use Disorder Market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share. The report also covers the Cocaine Use Disorder Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Cocaine Use Disorder Companies and Therapies

• Embera NeuroTherapeutics Inc.: EMB-001
• Novartis Pharmaceuticals: NS2359
• Seattle Institute for Biomedical and Clinical Research: Quetiapine

To know more about Cocaine Use Disorder Companies working in the treatment market, visit @ Cocaine Use Disorder Clinical Trials and Therapeutic Assessment

Cocaine Use Disorder Market Drivers

• Rising Global Prevalence of Cocaine Use

Increasing cocaine consumption across North America, Europe, and parts of Latin America has led to a growing patient population, directly expanding the demand for effective treatment and management options.

• High Unmet Need Due to Lack of Approved Pharmacotherapies

The absence of FDA-approved medications for cocaine use disorder has created a significant therapeutic gap, encouraging research activity and investment in novel pharmacological and behavioral interventions.

• Growing Awareness and Destigmatization of Substance Use Disorders

Improved public health awareness, shifting social attitudes, and recognition of addiction as a medical condition are driving higher diagnosis rates and greater willingness to seek treatment.

• Advancements in Neuroscience and Addiction Research

Deeper understanding of dopamine pathways, reward circuitry, and neuroplasticity is supporting the development of targeted therapies, vaccines, and neuromodulation-based approaches.

• Integration of Digital Therapeutics and Behavioral Interventions

The adoption of digital health platforms, telemedicine, and app-based cognitive behavioral therapies is enhancing treatment reach, adherence, and long-term patient engagement.

Cocaine Use Disorder Market Barriers

• Lack of Approved Drug Therapies

Despite extensive research, no pharmacological treatment has yet received regulatory approval, limiting therapeutic options and slowing commercial market expansion.

• High Clinical Trial Failure Rates

Addiction trials face challenges such as high dropout rates, relapse variability, and placebo effects, increasing development risks and discouraging investment.

• Stigma and Underdiagnosis

Persistent social stigma and fear of legal or social consequences prevent many individuals from seeking medical help, resulting in a large untreated population.

• Complex and Heterogeneous Disease Pathophysiology

Variability in patterns of cocaine use, comorbid psychiatric conditions, and polysubstance abuse complicates patient stratification and treatment standardization.

• Limited Reimbursement and Funding Constraints

Inadequate insurance coverage for addiction treatments and behavioral therapies restrict patient access and reduce the commercial attractiveness of new therapies.

• Regulatory and Ethical Challenges

Conducting clinical trials in substance use disorders involves strict regulatory oversight, ethical concerns, and recruitment difficulties, which can delay product development timelines.

Scope of the Cocaine Use Disorder Market Report

• Coverage- 7MM
• Study Period- 2020-2034· 
• Cocaine Use Disorder Companies- STALICLA, Embera NeuroTherapeutics, and others.
• Cocaine Use Disorder Therapies- EMB-001, NS2359, AFQ056, Buprenorphine + Naltrexone, Quetiapine, Risperidone, Brexpiprazole, and others.
• Cocaine Use Disorder Therapeutic Assessment: Cocaine Use Disorder current marketed and Cocaine Use Disorder emerging therapies
• Cocaine Use Disorder Market Dynamics: Cocaine Use Disorder market drivers and Cocaine Use Disorder market barriers
• Cocaine Use Disorder Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Cocaine Use Disorder Unmet Needs, KOL’s views, Analyst’s views, Cocaine Use Disorder Market Access and Reimbursement

Discover more about therapies set to grab the major Cocaine Use Disorder Market Share @ Cocaine Use Disorder Treatment Market

Table of Contents

1. Key Insights

2. Cocaine Use Disorder Market Report Introduction

3. Cocaine Use Disorder Executive Summary

4. Cocaine Use Disorder Key Events

5. Cocaine Use Disorder Epidemiology and Market Forecast Methodology

6. Cocaine Use Disorder Market Overview at a Glance

7. Cocaine Use Disorder Disease Background and Overview

8. Cocaine Use Disorder Epidemiology and Patient Population

9. Cocaine Use Disorder Patient Journey

10. Cocaine Use Disorder Marketed Drugs

11. Cocaine Use Disorder Emerging Drugs

12. Cocaine Use Disorder: 7MM Analysis

13. Cocaine Use Disorder Unmet Needs

14. Cocaine Use Disorder SWOT Analysis

15. Cocaine Use Disorder KOL Views

16. Cocaine Use Disorder Market Access and Reimbursement

17. Appendix

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight

About Us

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.